Quarterly report pursuant to Section 13 or 15(d)

Equity (Tables)

v3.24.1.1.u2
Equity (Tables)
 9 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Black-Scholes Option Pricing Model The fair values of the Company’s options were estimated at the dates of grant using a Black-Scholes option pricing model with the following assumptions:
    Nine Months Ended
March 31,
2024		  
Exercise price   $ 0.59 – 0.97  
Expected term (years)     4.00 – 4.75  
Volatility     71 – 75 %
Risk-free interest rate     4.42 – 4.66 %
Dividend yield     0 %
Weighted Average Grant Date Fair Value of Options granted during the period   $ 0.35  
Schedule of Compensation Expense Related to Our Stock-Based Awards Compensation expense related to our stock-based awards described above was as follows (in thousands):
    Three Months Ended
March 31,		     Nine Months Ended
March 31,		  
    2024     2023     2024     2023  
Research and Development   $ 132     $ 1,120     $ 783     $ 3,171  
General and Administrative   $ 777     $ 2,090     $ 2,201     $ 4,283  
Cost of Revenue   $ 35      
—
     $ 159          
Total   $ 944     $ 3,210     $ 3,144     $ 7,454  

 
Schedule of Unrecognized Stock-Based Compensation Expense and Weighted-Average Years Unrecognized stock-based compensation expense and weighted-average years to be recognized are as follows (in thousands):
    As of March 31, 2024  
    Unrecognized
stock-based
compensation		     Weighted-
average years
to be recognized		  
Options   $ 757       1.61  
Restricted stock units   $ 6,039       1.84